|
Hyperglycemia
|
0.540 |
AlteredExpression
|
disease |
BEFREE |
AR, PKC protein levels and related signalling molecules were increased with hyperglycemia and oxidative stress.
|
31743046 |
2019 |
|
Hyperglycemia
|
0.540 |
Biomarker
|
disease |
BEFREE |
Apn has protective effects against hyperglycemia and can effectively enhance antioxidation, promote the secretion of insulin and reduce the accumulation of glycosylated products in T2DM mice; these effects were associated with inhibition of PKC and promotion of PKA signaling.
|
28954262 |
2017 |
|
Hyperglycemia
|
0.540 |
AlteredExpression
|
disease |
BEFREE |
Hyperglycemia induced the expression of PKC-beta1 and PKC-beta2; however, only inhibition of PKC-beta1 but not PKC-beta2 led to a significant decrease of FGF-2 levels.
|
19279131 |
2009 |
|
Hyperglycemia
|
0.540 |
Biomarker
|
disease |
CTD_human |
Inhibition of PKC beta by ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin.
|
17443133 |
2007 |
|
Hyperglycemia
|
0.540 |
Biomarker
|
disease |
RGD |
Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}.
|
15616014 |
2005 |
|
Hyperglycemia
|
0.540 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest that hmunc13 serves as a diacylglycerol-activated, PKC-independent signaling pathway capable of inducing apoptosis and that this pathway may contribute to the renal cell complications of hyperglycemia.
|
10233166 |
1999 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
RBCK1, a protein kinase CbetaI (PKCbetaI)-interacting protein, regulates PKCbeta-dependent function.
|
17121852 |
2007 |
|
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
RGD |
Differential induction of protein kinase C isoforms at the cardiac hypertrophy stage and congestive heart failure stage in Dahl salt-sensitive rats.
|
12887134 |
2003 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
These data suggest that the simultaneous knockdown of upstream atypical PKC protein and downstream DNA damage repairing mechanism would be a useful approach to combat CRC and to improve overall patients' survival rate.
|
31810137 |
2020 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
In this study, the role of atypical Protein Kinase C (aPKC) on CRC was investigated by using two inhibitors of that protein class: 1) ζ-Stat (8-hydroxynaphthalene-1,3,6-trisulfonic acid) is a specific inhibitor of PKC-ζ and 2) ICA-I 5-amino-1-(2,3-dihydroxy-4-hydroxymethyl)cyclopentyl)-1H-imidazole-4-carboxamide) is a specific inhibitor of PKC-ι.
|
29408512 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
BEFREE |
Additionally, hepatic insulin resistance, which is caused by diacylglycerol-mediated activation of protein kinase C epsilon (PKC
|
30692925 |
2018 |
|
Colorectal Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
One of the four analysed genes (PKCΒ) was significantly downregulated in CRC tissue, as revealed by real-time PCR and re-analysis of the GSE25062 and GSE25070 datasets.
|
25366420 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
We also detect signals specific to T2D-discordant twins in the GPR61 and PRKCB genes.
|
25502755 |
2014 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
In this study we have seen that TDH has an implication in EGFR based therapeutic approach in colorectal cancer via PKC mediated mechanism.
|
22543197 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
To examine the risk association of PKC-beta 1 gene (PRKCB1) polymorphisms and end-stage renal disease (ESRD) in an 8-year prospective cohort of Chinese patients with type 2 diabetes.
|
20736472 |
2010 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
BEFREE |
Our study indicates that PRKCB1 is a predictor for worsening of kidney disease in Japanese subjects with type 2 diabetes.
|
16567829 |
2006 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
CTD_human |
Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin.
|
15531508 |
2004 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the 5'-upstream region of the PKCbeta gene in Japanese patients with Type 2 diabetes.
|
15384959 |
2004 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
BEFREE |
The results indicate that transcriptional up-regulation of PKC-theta may at least partly contribute to the increased muscle PKC-theta signalling in T2DM, and that PKC-theta mRNA may be inversely related to in-vivo insulin sensitivity.
|
14636302 |
2003 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Pro-oncogenic factors that also release beta-catenin from the adherens complex and/or encourage translocation to the nucleus include ras, epidermal growth factor (EGF), c-erbB-2, PKC-betaII, MUC1, and PPAR-gamma, whereas anti-oncogenic factors that also inhibit nuclear beta-catenin signaling include transforming growth factor (TGF)-beta, retinoic acid, and vitamin D. Association of nuclear beta-catenin with the T cell factor (TCF)/lymphoid enhancer factor (LEF) family of transcription factors promotes the expression of several compounds that have important roles in the development and progression of colorectal carcinoma, namely: c-myc, cyclin D1, gastrin, cyclooxygenase (COX)-2, matrix metalloproteinase (MMP)-7, urokinase-type plasminogen activator receptor (aPAR), CD44 proteins, and P-glycoprotein.
|
11839557 |
2002 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
CTD_human |
Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids.
|
7705931 |
1995 |
|
Colorectal Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
We have previously reported decreased protein kinase C (PKC) enzyme activity in primary human colorectal carcinomas.
|
8404381 |
1993 |
|
Glioblastoma Multiforme
|
0.340 |
Biomarker
|
disease |
BEFREE |
PKC-ι promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway.
|
21419810 |
2011 |
|
Glioblastoma Multiforme
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Treatment of a panel of established GBM cell lines (U138MG, U87, U373 and C6) with pharmacological NFκB inhibitors (BAY117082, parthenolide, MG132, curcumin and arsenic trioxide) and NFκB-p65 siRNA markedly decreased the viability of GBMs as compared to inhibitors of other signaling pathways such as MAPKs (ERK, JNK and p38), PKC, EGFR and PI3K/Akt.
|
21040711 |
2011 |
|
Glioblastoma Multiforme
|
0.340 |
Biomarker
|
disease |
BEFREE |
Taken together, these data demonstrate that rapamycin-insensitive glioblastoma proliferation involves PKC-eta signaling.
|
16832347 |
2007 |